Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults

Trial Profile

Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs TAK 214 (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 28 Jun 2016 Results published in the Journal of Infectious Diseases
    • 12 May 2016 No of arms changed from 5 to 3. Also from primary end points, cohort 1 and cohort 2 separation and time frame for the cohort 2 is removed
    • 12 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top